RenovoRx Announces Date for Third Quarter 2026 Financial Results
RenovoRx, Inc. has scheduled the release of its third quarter 2026 financial results and business highlights for after market close on November 5, 2026.
Stocks · News reference
RenovoRx Management to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
RenovoRx, Inc. announced that its CEO and CFO will present at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RenovoRx Enrolls First Participant In PRISM-TAMP, “PDAC Regression And Intraoperative Surgical Margin With Neoadjuvant TAMP Study
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared
RenovoRx Announces Publication Of Peer-Reviewed Case Series In Case Reports In Oncology From Researchers At Hackensack Meridian Health’s Jersey Shore University Medical Center